Established in 1995 as a spin out from Oxford University,
Oxford BioMedica plc specialises in the development
of novel gene-based therapeutics for the treatment of
cancer, neuro-degenerative disease and other disorders
with major unmet clinical needs. The development pipeline
includes two novel anti-cancer products in clinical
trials and a gene therapy treatment for Parkinson’s
disease, which is in late preclinical studies. This
is underpinned by a broad research pipeline and over
70 patent families, about quarter of which are issued.
Oxford
BioMedica’s products use genes as the mediators
of a therapeutic effect and/or immune response. The
Company’s gene therapy products deliver therapeutic
molecules in vivo whilst its gene-based immunotherapy
products deliver genes that recruit the patient’s
immune system to mediate a therapeutic effect. The genes
are delivered by the Company’s highly engineered
viruses or cells.
BioMedica’s
lead product TroVax® is an anti-cancer therapeutic
vaccine expected to be useful against a broad range
of tumour types. It is entering Phase II trials in a
number of indications including colorectal and renal
cancer, and is expected to be ready for Phase III trials
at the end of 2003. The Company’s second cancer
product, MetXia®, is completing Phase I/II studies
in breast cancer.
Oxford
BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA. BioMedica has corporate
collaborations with Wyeth, IDM, Intervet, Aliga Pharmaceuticals,
Amersham and Arius Research.
Oxford
BioMedica plc was floated on the Alternative Investment
Market of the London Stock Exchange in December 1996,
and was promoted to the United Kingdom Listing Authority
Official List in April 2001 following a successful £35.5
million fund-raising. |
